EPCAM_PIG EPCAM ELISA tesk kit
- Known as:
- EPCAM_PIG EPCAM Enzyme-linked immunosorbent assay test tesk reagent
- Catalog number:
- gen16496
- Product Quantity:
- 1
- Category:
- Peptides
- Supplier:
- Other suppliers
- Gene target:
- EPCAM_PIG EPCAM ELISA tesk kit
Related genes to: EPCAM_PIG EPCAM ELISA tesk kit
- Gene:
- EPCAM NIH gene
- Name:
- epithelial cell adhesion molecule
- Previous symbol:
- M4S1, MIC18, TACSTD1
- Synonyms:
- Ly74, TROP1, GA733-2, EGP34, EGP40, EGP-2, KSA, CD326, Ep-CAM, HEA125, KS1/4, MK-1, MH99, MOC31, 323/A3, 17-1A, TACST-1, CO-17A, ESA
- Chromosome:
- 2p21
- Locus Type:
- gene with protein product
- Date approved:
- 1995-10-02
- Date modifiied:
- 2019-04-23
Related products to: EPCAM_PIG EPCAM ELISA tesk kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: EPCAM_PIG EPCAM ELISA tesk kit
- Lung cancer is frequently diagnosed after curative treatment windows have narrowed, creating a need for minimally invasive biomarkers that report tumor development at earlier stages. Extracellular vesicles (EVs) are promising analytical targets because they carry molecular cargo from their originating cells, but tumor-associated EV signals can be rare in blood and obscured in bulk measurements. Here, we present Cygnus (Cyclic-imaging gateway to nanovesicles underlying signature), an end-to-end workflow that integrates cyclic immunofluorescence imaging with multiscale analysis of individual EVs. Cygnus preserves vesicle-level measurements, quantifies marker co-expression, resolves EV subpopulations, and summarizes single-vesicle phenotypes into sample-level profiles. In a genetically engineered mouse model of lung adenocarcinoma, Cygnus revealed dynamic changes in EV protein composition and identified an EpCAM- and/or CTSH-positive EV subpopulation before tumors were detectable by radiography. In a pilot clinical cohort (n = 35), plasma EV profiling showed lung cancer-associated marker patterns compared with non-cancer controls and nominated a CTSH/PDL1/MET marker combination for future validation. These findings support multiplexed individual-EV profiling as a strategy for defining candidate lung cancer-associated EV signatures and position Cygnus as an integrated workflow for translating vesicle-level heterogeneity into sample-level EV profiles. - Source: PubMed
Publication date: 2026/08/25
Cho Mi HyeonChung YeinChoi YoonjeongCha BaekdongSong JayeonOh NuriJo AlaNg Thomas S CKim HyunhoWoo Hyun-KyungKim Chang HyunCastro Cesar MMiller Miles ALee Hakho - The prognosis of epithelial ovarian cancer (EOC) after comprehensive treatment remains unsatisfactory. This study aimed to evaluate the feasibility of enriching and detecting circulating tumor cells (CTCs) in peripheral blood from EOC patients using EpCAM antibody-based microfluidic chips, investigate the prognostic value of CTC PD-L1 expression, and analyze the cellular heterogeneity of ovarian cancer through re-analysis of publicly available single-cell RNA sequencing data. - Source: PubMed
Publication date: 2026/08/10
Zhang LinLyu HongqingTong XiaLou Shuai - Primary liver cancer lacks robust biomarkers for anti-PD-1/PD-L1 therapy. Methods: We engineered peptide-functionalized magnetic nanobeads (Pep@MNPs) for high-efficiency, EpCAM-dependent capture of circulating tumor cells (CTCs). This nanotechnology-based platform enabled a precise fluorescence quantitative system (cTPS) associate with immunotherapy outcomes in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. The Pep@MNPs system revealed a significant correlation between high CTC PD-L1 expression and therapeutic response. Patients with baseline cTPS (≥20%) achieved a superior objective response rate compared to the low-expression group (40% vs. 0%; P = 0.005). Utilizing this nanobead-enabled quantification, cTPS patients demonstrated significantly prolonged progression-free survival (median 48.29 vs. 5.86 weeks, P = 0.005) and overall survival (median undefined vs. 25.71 weeks, P = 0.004). Furthermore, multivariate Cox regression confirmed cTPS as a robust independent predictor for both PFS and OS (both P = 0.005) after adjusting for clinical variables. This peptide-nanobead liquid biopsy strategy effectively stratifies patients benefiting from PD-1 inhibitors, highlighting its potential as a precise theranostic tool for clinical monitoring. - Source: PubMed
Publication date: 2026/08/18
Li XuejieTian ShanFan LinyangWang GuangpengMa TianyiLiao HaiqiZhang YuhanHu ZhiyuanWang ZheXu XiaohongChen Yongyi - Gastric cancer often presents at advanced stages, limiting treatment outcomes. Circulating tumor cells (CTCs), particularly those undergoing epithelial-mesenchymal transition (EMT), have emerged as promising biomarkers for real-time disease monitoring. Using magnetic-activated cell sorting (MACS), we enriched both epithelial (EpCAM) and mesenchymal (CD90) CTCs and evaluated the expression of the tumor-suppressive microRNA miR-29b in CTCs of gastric cancer patients. This study aimed to explore the clinical relevance of perioperative CTC phenotypes and miR-29b as potential diagnostic and prognostic markers. We conducted a multi-phase study integrating systematic review, bioinformatics, and experimental analyses to investigate CTC phenotypes and ECM-associated gene expression in GC. Peripheral blood samples were collected from 30 treatment-naïve gastric cancer patients at two time points: before initiation of therapy and 1 month after curative-intent gastrectomy. Circulating tumor cells (CTCs) were isolated using CD45-negative magnetic-activated cell sorting (MACS). Immunofluorescence staining was performed to phenotype CTCs based on EpCAM (epithelial) and CD90 (mesenchymal) expression. Total RNA was extracted from tumor tissues and isolated CTCs to evaluate ECM-related genes and miR-29b expression using quantitative real-time PCR. Bioinformatics-guided gene selection and statistical analysis were used to assess diagnostic and prognostic relevance. CTCs were detected in 83.3% (25/30) of gastric cancer patients prior to treatment. Mesenchymal CTCs (CD90) were markedly more frequent than epithelial CTCs (EpCAM), with mean baseline counts of 14.07 versus 0.5 cells per 10 mL of blood, respectively. Following gastrectomy and chemotherapy, mesenchymal CTCs significantly declined (mean: 1.18; = 0.0064), while epithelial CTCs were nearly undetectable ( = 0.0246). Based on perioperative CTC dynamics, patients were stratified into three risk groups: high-risk (16%), intermediate-risk (68%), and low-risk (16%). All observed deaths occurred in the high-risk group during 14 months of follow-up, with Kaplan-Meier analysis showing significantly lower survival in this group ( = 0.0107). Expression analysis revealed significant downregulation of miR-29b in tumor tissues (fold change = 0.5163; = 0.0136) and in CTCs (fold change = 0.2049; < 0.0001) compared to healthy controls. Although miR-29b levels were broadly downregulated in gastric cancer patients, no significant differences were observed among clinicopathological subgroups within the patient cohort. ROC analysis showed strong diagnostic performance of miR-29b in tissue (AUC = 0.883, 95% CI: 0.798-0.969), with 96.7% sensitivity and 70% specificity. CD90 serves as a sensitive mesenchymal marker for detecting CTCs that lack epithelial features, enabling more comprehensive identification of aggressive CTC phenotypes in gastric cancer. Moreover, the perioperative dynamics of CTCs-especially postoperative increases-provide a valuable tool for patient risk stratification and survival prediction. Importantly, our findings suggest that miR-29b expression in CTCs, together with perioperative CTC dynamics, may serve as a non-invasive biomarker for monitoring disease progression and recurrence in gastric cancer. - Source: PubMed
Publication date: 2026/08/19
Eskandarion Mohammad RezaEskandarieh ShararehShakoori Farahani AbbasGhanbari Mardasi FaridehMahmoodzadeh HabibollahRoudini KamranShahi FarhadOghabian Mohammad AliTaher MohammadShirkoohi Reza - High neutrophil-lymphocyte ratio (NLR) and neutrophil extracellular traps (NETs) are associated with poor overall survival in many cancers but are currently remain without safe effective therapy until subtype elucidation identifies a targetable molecular subtype whose inhibition will not compromise homeostatic pathogen defense. We tested the hypothesis that increased circulating NET-forming neutrophils (NETNs) expressing the cell-surface dual endothelin-1/signal receptor (DEspR) comprise a subtype that predicts poor survival outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) receiving first-line chemotherapy-immunotherapy (chemo-IO), because peripheral levels of DEspR neutrophils and NETNs are increased in neutrophil-mediated secondary tissue injury during sterile inflammation across different diseases in which high NLR is associated with disease progression or exacerbation. - Source: PubMed
Publication date: 2026/08/05
Herrera Victoria L MMahdaviani KianaChoi JacquelineChen Sin-HanGunn EliotStadnicki KurtisMortazavi-Zadeh AnaisLok Judith JTapan UmitRuiz-Opazo Nelson